JBCPL has its presence in the International market for over two
decades.
Its operations span over 50 countries around the globe. The company
exports drug intermediates, bulk drugs and formulations to USA,
Europe, Africa, CIS countries, Middle East, and South East Asia.
The company was quick to respond to the opportunity of a liberalized
Russian economy by establishing its representative office in Moscow
& Kiev in 1994.This facilitated administrative and regulatory
procedure for a smooth entry in the Russian market. Unfulfilling
needs in these markets gave rise to a strong sales force of 45 medical
representative and 35 distributors / Importers in Russia and CIS
alone. A similar activity came up with opening of representative
office in Vietnam, Uganda, Tanzania & Sudan. The company has
gone global with its strong marketing tie-ups in SriLanka, Malaysia,
Vietnam & Myanmar to promote its specialty formulation. The
company also has a technical collaboration in Austria to manufacture
and market their products.
The company is geared to meet the challenges of Post-GATT ERA having
a strong regulatory team, which supports the international Division
and helps in formulation development, analytical testing, quality
assurance and medical
REGULATORY ACHIEVEMENTS:
Success comes through achievements. So is our regulatory team who
are successful in filling dossiers in more than 50 countries around
the globe.
- NDDS patents granted in United States of America for controlled
release formulations of Ranitidine and Tropical dental formulation
of Metronidazole and Chlorhexidine for Periodontal treatment.
- Metronidazole - Approved by US FDA and Therapeutic Goods Administration
(TGA), Australia.
- US Patent for novel pharmaceutical formulation of Metronidazole
for dental application.
- Patents also granted in South Africa for controlled release
formulations Ranitidine and Nifedipine 30 mg extended release
tablets.
- Patent application submitted “Pharmaceutical composition
for controlled drug delivery systems” covering new NDDS
formulations of Ciprofloxacin OD and Ofloxacin OD.
- ANDA’s filled for Ciproflocaxin and Flucanozole.
With a formidable turnover of Rs. 162.29 crs it is contributing
to 52% to the company’s total turnover, thus JBCPL is truly
an International Marketing Company.
Company’s continuous focus on brand building has reaped rich
dividends, due to which many of our brands have attained leadership
status in their respective markets.
With consistent and focused promotion, JBCPL has ensured whooping
growths year after year which is evident from the sales graph shown
below
|